AOD-9604 is a synthetic peptide corresponding to a modified C-terminal fragment of human growth hormone (roughly residues 176-191, with an added N-terminal tyrosine). Because it represents only a fragment rather than the intact hormone, it is studied as a tool compound for isolating specific metabolic-signaling questions from growth hormone's much broader activity.
What it is
As a defined 15-residue fragment, AOD-9604 is interpreted using general amino acid sequence principles. It sits within the broader family of growth-hormone-axis tool compounds, but occupies a distinct position: rather than stimulating hormone release, it reproduces only a narrow C-terminal behavior of the parent molecule.
Why researchers study it
The appeal of a fragment is specificity. By removing the receptor-activating portion of growth hormone, researchers can probe a single metabolic question without provoking the full-hormone response. Its proposed mechanism of action centers on lipid-metabolism readouts in model adipocyte systems, making it useful for studies where the confounding effects of intact GH would obscure the signal.
How it differs from secretagogues
It is instructive to contrast AOD-9604 with growth-hormone secretagogues such as ipamorelin, which act upstream to trigger endogenous GH release. AOD-9604 works downstream of that step, so the two categories answer very different experimental questions even though both relate to the GH axis.
Preclinical footprint
The fragment has been examined in cell-culture and animal model systems, summarized in its preclinical research article. These studies frame it strictly as a controlled-model probe.
Research context and documentation
Fragment identity is easy to get wrong because closely related sequences share many properties, so documentation is critical — see how to read a COA and HPLC vs. mass spectrometry. Proper reconstitution and storage of characterized material also protect experimental integrity.
Key questions for future research
Several questions remain central to the compound’s scientific value: which molecular target first recognizes the fragment, how sequence modifications affect that interaction, and which observed metabolic markers are direct rather than downstream consequences. Experiments that combine target-identification methods with pathway perturbation would be more informative than relying on a single phenotypic endpoint. Researchers must also distinguish the modified AOD-9604 sequence from nearby native GH fragments, since even one terminal residue can alter analytical behavior and activity. Framing the compound around these unresolved questions keeps the overview appropriately evidence-based and highlights why identity, controls, and model selection are inseparable from mechanistic interpretation.
Product page: AOD-9604 research vials.
Research Use Only. Supplied strictly for laboratory research and development — not for human or veterinary use, consumption, or any therapeutic or diagnostic purpose. This article is research education, not usage guidance.